446 related articles for article (PubMed ID: 7212408)
1. Activated coagulation time in monitoring heparinized dogs.
Green RA
Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
[TBL] [Abstract][Full Text] [Related]
2. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
Greene CE; Meriwether E
Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
[TBL] [Abstract][Full Text] [Related]
3. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
Hellebrekers LJ; Slappendel RJ; van den Brom WE
Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
[TBL] [Abstract][Full Text] [Related]
4. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
5. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
Wilkerson RD; Conran PB; Greene SL
Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
[TBL] [Abstract][Full Text] [Related]
6. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
7. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the red blood cell mass of horses: toxic effect of heparin anticoagulant therapy.
Duncan SG; Meyers KM; Reed SM
Am J Vet Res; 1983 Dec; 44(12):2271-6. PubMed ID: 6660615
[TBL] [Abstract][Full Text] [Related]
9. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs.
Diquélou A; Barbaste C; Gabaig AM; Trumel C; Abella-Bourges N; Guelfi JF; Bousquet Mélou A
Vet Clin Pathol; 2005 Sep; 34(3):237-42. PubMed ID: 16134071
[TBL] [Abstract][Full Text] [Related]
11. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
12. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
Varah N; Smith J; Baugh RF
Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
[TBL] [Abstract][Full Text] [Related]
13. Changes in anticoagulation in dogs assayed by three methods.
Harrison HN; Gutterman B; Haynie M; Weintraub H; Brandt B
Lab Anim Sci; 1976 Dec; 26(6 Pt 1):917-21. PubMed ID: 1018478
[TBL] [Abstract][Full Text] [Related]
14. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
[TBL] [Abstract][Full Text] [Related]
15. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
[TBL] [Abstract][Full Text] [Related]
16. Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin.
Gerhards H; Eberhardt C
Am J Vet Res; 1988 Jan; 49(1):13-8. PubMed ID: 3354959
[TBL] [Abstract][Full Text] [Related]
17. Sonoclot® evaluation of single- and multiple-dose subcutaneous unfractionated heparin therapy in healthy adult dogs.
Babski DM; Brainard BM; Ralph AG; Pittman JR; Koenig A
J Vet Intern Med; 2012; 26(3):631-8. PubMed ID: 22435404
[TBL] [Abstract][Full Text] [Related]
18. The APTT response of pregnant plasma to unfractionated heparin.
Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
[TBL] [Abstract][Full Text] [Related]
19. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Cavusoglu E; Lakhani M; Marmur JD
J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
[TBL] [Abstract][Full Text] [Related]
20. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
